PD-L1 inhibitors in the pipeline: Promise and progress

PD-L1 inhibitors in the pipeline: Promise and progress

Checkpoint inhibitors have improved survival for patients with melanoma, non-small-cell lung cancer (NSCLC), bladder, head and neck and other cancers. Antibodies against PD-L1, including atezolizumab, avelumab and durvalumab, are also being developed and have been approved for various cancers. Compa...

Full description

Bibliographic Details
Main Authors: Vito Vanella, Lucia Festino, Martina Strudel, Ester Simeone, Antonio M. Grimaldi, Paolo A. Ascierto
Format: Article
Language:English
Published: Taylor & Francis Group 2018-01-01
Series:OncoImmunology
Subjects:
atezolizumab
avelumab
bladder cancer
durvalumab
immunotherapy
lung cancer
melanoma
merkel cell carcinoma
pd-l1
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1365209

Internet

http://dx.doi.org/10.1080/2162402X.2017.1365209

Similar Items